-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, August 5 News On August 3, Nanjing Chia Tai Tianqing submitted four types of generic listings of Tedizolamide Phosphate Tablets, and the application was undertaken by CDE
.
As early as June this year, the company has successfully submitted an application for the imitation of Tedizolamide Phosphate for Injection in Category 4, and the relevant acceptance number is currently under review and approval
.
.
As early as June this year, the company has successfully submitted an application for the imitation of Tedizolamide Phosphate for Injection in Category 4, and the relevant acceptance number is currently under review and approval
.
Figure 1: The related situation of Tedizolamide declared by Nanjing Zhengda Tianqing
Source: CDE official website
In March 2019, Bayer's tedizolamide phosphate tablets and injections were approved for marketing by NMPA, and the approved indications are acute skin and skin tissue infections in adults caused by gram-positive bacteria
.
Compared with the first-generation oxazolidinone antibiotic, linezolid, Tedizolid has two main advantages: one is that it is used once a day for six days, which is more convenient than linezolid twice a day for ten days; There are injections and tablets in the dosage form, which is convenient for clinical switching, reduces the patient's hospitalization time, and thus reduces the cost
.
.
Compared with the first-generation oxazolidinone antibiotic, linezolid, Tedizolid has two main advantages: one is that it is used once a day for six days, which is more convenient than linezolid twice a day for ten days; There are injections and tablets in the dosage form, which is convenient for clinical switching, reduces the patient's hospitalization time, and thus reduces the cost
.
Figure 2: Current situation of companies that have applied for imitation listing of Tedizolamide and are under review
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In terms of domestically produced generic drugs, Beijing Fuyuan Pharmaceutical submitted an application for the listing of Tedizolamide Phosphate Tablets in April this year.
It was the first company to declare tablets , and Nanjing Chia Tai Tianqing was the second
.
Yangzijiang submitted a listing application for Tedizolamide Phosphate for Injection in 2019.
Ruiyang Pharmaceuticals and Nanjing Zhengda Tianqing reported production this year
.
It was the first company to declare tablets , and Nanjing Chia Tai Tianqing was the second
.
Yangzijiang submitted a listing application for Tedizolamide Phosphate for Injection in 2019.
Ruiyang Pharmaceuticals and Nanjing Zhengda Tianqing reported production this year
.
From the time of declaration, Nanjing CP Tianqing is not the first company to declare, but the dosage form is the most complete.
The subsequent approval for listing is expected to form a siege and strive to grab Bayer's market share
.
The subsequent approval for listing is expected to form a siege and strive to grab Bayer's market share
.
Data source: CDE official website, Minet database
Medical Network, August 5 News On August 3, Nanjing Chia Tai Tianqing submitted four types of generic listings of Tedizolamide Phosphate Tablets, and the application was undertaken by CDE
.
As early as June this year, the company has successfully submitted an application for the imitation of Tedizolamide Phosphate for Injection in Category 4, and the relevant acceptance number is currently under review and approval
.
.
As early as June this year, the company has successfully submitted an application for the imitation of Tedizolamide Phosphate for Injection in Category 4, and the relevant acceptance number is currently under review and approval
.
Figure 1: The related situation of Tedizolamide declared by Nanjing Zhengda Tianqing
Source: CDE official website
In March 2019, Bayer's tedizolamide phosphate tablets and injections were approved for marketing by NMPA, and the approved indications are acute skin and skin tissue infections in adults caused by gram-positive bacteria
.
Compared with the first-generation oxazolidinone antibiotic, linezolid, Tedizolid has two main advantages: one is that it is used once a day for six days, which is more convenient than linezolid twice a day for ten days; There are injections and tablets in the dosage form, which is convenient for clinical switching, reduces the patient's hospitalization time, and thus reduces the cost
.
.
Compared with the first-generation oxazolidinone antibiotic, linezolid, Tedizolid has two main advantages: one is that it is used once a day for six days, which is more convenient than linezolid twice a day for ten days; There are injections and tablets in the dosage form, which is convenient for clinical switching, reduces the patient's hospitalization time, and thus reduces the cost
.
Figure 2: Current situation of companies that have applied for imitation listing of Tedizolamide and are under review
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In terms of domestically produced generic drugs, Beijing Fuyuan Pharmaceutical submitted an application for the listing of Tedizolamide Phosphate Tablets in April this year.
It was the first company to declare tablets , and Nanjing Chia Tai Tianqing was the second
.
Yangzijiang submitted a listing application for Tedizolamide Phosphate for Injection in 2019.
Ruiyang Pharmaceuticals and Nanjing Zhengda Tianqing reported production this year
.
It was the first company to declare tablets , and Nanjing Chia Tai Tianqing was the second
.
Yangzijiang submitted a listing application for Tedizolamide Phosphate for Injection in 2019.
Ruiyang Pharmaceuticals and Nanjing Zhengda Tianqing reported production this year
.
From the time of declaration, Nanjing CP Tianqing is not the first company to declare, but the dosage form is the most complete.
The subsequent approval for listing is expected to form a siege and strive to grab Bayer's market share
.
The subsequent approval for listing is expected to form a siege and strive to grab Bayer's market share
.
Data source: CDE official website, Minet database
Medical Network, August 5 News On August 3, Nanjing Chia Tai Tianqing submitted four types of generic listings of Tedizolamide Phosphate Tablets, and the application was undertaken by CDE
.
As early as June this year, the company has successfully submitted an application for the imitation of Tedizolamide Phosphate for Injection in Category 4, and the relevant acceptance number is currently under review and approval
.
.
As early as June this year, the company has successfully submitted an application for the imitation of Tedizolamide Phosphate for Injection in Category 4, and the relevant acceptance number is currently under review and approval
.
Figure 1: The related situation of Tedizolamide declared by Nanjing Zhengda Tianqing
Source: CDE official website
In March 2019, Bayer's tedizolamide phosphate tablets and injections were approved for marketing by NMPA, and the approved indications are acute skin and skin tissue infections in adults caused by gram-positive bacteria
.
Compared with the first-generation oxazolidinone antibiotic, linezolid, Tedizolid has two main advantages: one is that it is used once a day for six days, which is more convenient than linezolid twice a day for ten days; There are injections and tablets in the dosage form, which is convenient for clinical switching, reduces the patient's hospitalization time, and thus reduces the cost
.
.
Compared with the first-generation oxazolidinone antibiotic, linezolid, Tedizolid has two main advantages: one is that it is used once a day for six days, which is more convenient than linezolid twice a day for ten days; There are injections and tablets in the dosage form, which is convenient for clinical switching, reduces the patient's hospitalization time, and thus reduces the cost
.
Figure 2: Current situation of companies that have applied for imitation listing of Tedizolamide and are under review
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In terms of domestically produced generic drugs, Beijing Fuyuan Pharmaceutical submitted an application for the listing of Tedizolamide Phosphate Tablets in April this year.
It was the first company to declare tablets , and Nanjing Chia Tai Tianqing was the second
.
Yangzijiang submitted a listing application for Tedizolamide Phosphate for Injection in 2019.
Ruiyang Pharmaceuticals and Nanjing Zhengda Tianqing reported production this year
.
Pharmaceutical Pharmaceutical Pharmaceutical Enterprise Enterprise EnterpriseIt was the first company to declare tablets , and Nanjing Chia Tai Tianqing was the second
.
Yangzijiang submitted a listing application for Tedizolamide Phosphate for Injection in 2019.
Ruiyang Pharmaceuticals and Nanjing Zhengda Tianqing reported production this year
.
From the time of declaration, Nanjing CP Tianqing is not the first company to declare, but the dosage form is the most complete.
The subsequent approval for listing is expected to form a siege and strive to grab Bayer's market share
.
The subsequent approval for listing is expected to form a siege and strive to grab Bayer's market share
.
Data source: CDE official website, Minet database
